Generic Rezlidhia Availability
Last updated on Apr 10, 2025.
Rezlidhia is a brand name of olutasidenib, approved by the FDA in the following formulation(s):
REZLIDHIA (olutasidenib - capsule;oral)
-
Manufacturer: RIGEL PHARMS
Approval date: December 1, 2022
Strength(s): 150MG [RLD]
Is there a generic version of Rezlidhia available?
No. There is currently no therapeutically equivalent version of Rezlidhia available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Rezlidhia. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
Patent 10,414,752
Issued: September 17, 2019
Inventor(s): Lin Jian & Ericsson Anna & Campbell Ann-Marie & Gustafson Gary & Wang Zhongguo & Diebold R. Bruce & Ashwell Susan & Lancia & Jr. David R. & Caravella Justin Andrew & Lu Wei
Assignee(s): Forma Therapeutics, Inc.The application relates to an inhibitor of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula (I-13):
Patent expiration dates:
- September 18, 2035✓
- September 18, 2035
-
Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
Patent 10,532,047
Issued: January 14, 2020
Inventor(s): Luke George P.
Assignee(s): FORMA Therapeutics, Inc.The present disclosure reports solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile.
Patent expiration dates:
- May 16, 2039✓
- May 16, 2039
-
Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
Patent 10,550,098
Issued: February 4, 2020
Inventor(s): Lin Jian & Ericsson Anna & Campbell Ann-Marie & Gustafson Gary & Wang Zhongguo & Diebold R. Bruce & Ashwell Susan & Lancia & Jr. David R. & Caravella Justin Andrew & Lu Wei
Assignee(s): Forma Therapeutics, Inc.The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula:
Patent expiration dates:
- September 18, 2035✓
- September 18, 2035
-
Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
Patent 10,959,994
Issued: March 30, 2021
Inventor(s): Luke George P. & Sheth Pratik
Assignee(s): FORMA Therapeutics, Inc.The present disclosure reports solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile.
Patent expiration dates:
- May 16, 2039✓
- May 16, 2039
-
Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
Patent 11,013,733
Issued: May 25, 2021
Inventor(s): Ashwell; Susan et al.
Assignee(s): FORMA Therapeutics, Inc. (Watertown, MA)Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.
Patent expiration dates:
- May 16, 2039✓
- May 16, 2039
-
Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
Patent 11,013,734
Issued: May 25, 2021
Inventor(s): Kelly; Patrick F. et al.
Assignee(s): FORMA Therapeutics, Inc. (Watertown, MA)Methods of treating patients diagnosed with AML or MDS harboring mutant IDH-1 include detecting an IDH1 mutation and the therapeutic administration of an inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA) or cytarabine.
Patent expiration dates:
- May 16, 2039✓
- May 16, 2039
-
Inhibiting mutant IDH-1
Patent 11,376,246
Issued: July 5, 2022
Inventor(s): Kelly; Patrick F. et al.
Assignee(s): FORMA Therapeutics, Inc. (Watertown, MA)Methods of treating patients diagnosed with cancer harboring an IDH-1 mutation are provided, including the therapeutic administration of a certain inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA).
Patent expiration dates:
- May 16, 2039✓
- May 16, 2039
-
Treating patients harboring an isocitrate dehydrogenase 1 (IDH-1) mutation
Patent 11,497,743
Issued: November 15, 2022
Inventor(s): Kelly; Patrick F. et al.
Assignee(s): FORMA Therapeutics, Inc. (Watertown, MA)Methods of treating patients diagnosed with AML or MDS harboring mutant IDH-1 include detecting an IDH1 mutation and the therapeutic administration of an inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA) or cytarabine.
Patent expiration dates:
- May 16, 2039✓
- May 16, 2039
-
Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
Patent 11,498,913
Issued: November 15, 2022
Inventor(s): Lin; Jian et al.
Assignee(s): FORMA Therapeutics, Inc. (Watertown, MA)The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: ##STR00001##
where A, U, W.sub.1, W.sub.2, W.sub.3, R.sub.1-R.sub.6, and R.sub.9 are described herein.Patent expiration dates:
- September 18, 2035✓
- September 18, 2035
-
Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
Patent 11,723,905
Issued: August 15, 2023
Inventor(s): Luke; George P. et al.
Assignee(s): FORMA Therapeutics, Inc. (Watertown, MA)The present disclosure reports solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile.
Patent expiration dates:
- November 12, 2039✓
- November 12, 2039
-
Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
Patent 11,738,018
Issued: August 29, 2023
Inventor(s): Ashwell; Susan et al.
Assignee(s): FORMA Therapeuetics, Inc. (Watertown, MA)Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.
Patent expiration dates:
- July 17, 2039✓
- July 17, 2039
-
Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
Patent 12,053,463
Issued: August 6, 2024
Inventor(s): Luke; George P. et al.
Assignee(s): FORMA Therapeutics, Inc. (Watertown, MA)The present disclosure reports solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile.
Patent expiration dates:
- May 16, 2039✓✓
- May 16, 2039
-
Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
Patent 9,834,539
Issued: December 5, 2017
Inventor(s): Lin Jian & Ericsson Anna & Campbell Ann-Marie & Gustafson Gary & Wang Zhongguo & Diebold R. Bruce & Ashwell Susan & Lancia & Jr. David R. & Caravella Justin Andrew & Lu Wei
Assignee(s): FORMA Therapeutics, Inc.The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula:
Patent expiration dates:
- September 18, 2035✓✓✓
- September 18, 2035
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- December 1, 2027 - NEW CHEMICAL ENTITY
- December 1, 2029 - TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH A SUSCEPTIBLE ISOCITRATE DEHYDROGENASE-1 (IDH1) MUTATION AS DETECTED BY AN FDA-APPROVED TEST
More about Rezlidhia (olutasidenib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous antineoplastics
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
